Capsid inhibitors: Scientists find novel, potent HIV agents with long-acting potential | CROI
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Researchersidentified novel HIV-1 capsid inhibitors (CAIs) with uniquely potent antiviral activity and a favorable resistance profile orthogonal to existing antiretrovirals (ARVs).
Why this matters
While HIV capsid (CA) plays an essential role in multiple stages of the viral life cycle, it remained an unexplored target for ARV therapy.
They identified GS-CA1, an exemplified member of a novel class of CAIs, as a highly potent inhibitor of HIV-1 replication in T cell lines (EC50 = 0.24 nM) that displays similar potency against multiple HIV-1 clinical isolates from all major clades in huma...